Idogen presents at Biostock Live on February 13, 2020
![](https://mb.cision.com/Public/12368/3030091/99f9ae6761502475_800x800ar.jpg)
Idogen will attend the BioStock Live investor event in Stockholm, on February 13.
The company will be presented by CEO Anders Karlsson.
Register here
For additional information, please contact:
Anders Karlsson, CEO Idogen AB
Tel: +46 (0) 709 18 00 10
E-mail: anders.karlsson@idogen.com
Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com